ECOG-ACRIN Operations Office – Boston Frontier Science 900 Commonwealth Avenue Boston, MA 02215 (617) 632-3610 Fax: (617) 632-2990 Randomization: (617) 632-2022 Group Chair: Robert L. Comis, M.D. and Mitchell Schnall, M.D. Jean MacDonald, Director of Research Operations Group Statistician: Robert Gray, Ph.D. and Constantine Gatsonis, Ph.D. Mary Steele, Director of Group Administration July 31, 2014 Martha Kruhm, MS RAC Head, Protocol and Information Office Quality Assurance Section CTEP, DCT, NCI 6130 Executive Blvd, EPN Room 7000 Bethesda, MD 20892 Dear Ms. Kruhm: Enclosed is Addendum #9 to E2809, Androgen Receptor Modulation Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy. The following revisions to E2809 protocol have been made in this addendum: Section Change 1. Cover Page Updated the version date. Inserted into the first and second bullet points the phrase "confirmed on 2. Section 6.1.4 two consecutive additional determinations taken at least 4 weeks apart," to more clearly define undetectable PSA. The following revisions to E2809 Informed Consent Document have been made in this addendum: Section Change 1. Cover Page Updated the version date. "What side effects or Updated the risk section language to correspond with the condensed 2. risks can I expect from risk lists format. being in the study?" "What side effects or 3. risks can I expect from Inserted condensed risk list for Bicalutamide. being in the study?" If you have any questions regarding this addendum, please contact
[email protected] or 617-632-3610.